
Program Access
Watch NowProgram Description
First-Line Maintenance Therapy for Advanced Ovarian Cancer: Pinpointing a Place for PARP Inhibitors
Dr. Alon Altman, FRCSC
University of Manitoba
CancerCare Manitoba, Shared Health
Winnipeg, Manitoba
Individualizing First-Line Ovarian Cancer Maintenance Therapy: A Practical Approach
Dr. Prafull Ghatage, FRCSC
University of Calgary
Tom Baker Cancer Centre
Calgary, Alberta
Key learning objectives:
- Summarize the rationale for using PARP inhibitors in the front-line maintenance setting for patients with advanced ovarian cancer
- Evaluate the latest evidence for current and emerging PARP inhibitors used in the front-line maintenance setting for patients with advanced ovarian cancer
- Propose strategies to individualize and optimize the use of PARP inhibitors as maintenance treatment based on patient, disease, and drug characteristics
Sponsorship
This activity is supported by an educational grant from GlaxoSmithKline Inc.
Back To Programs